Estamos realizando la búsqueda. Por favor, espere...

 Detalle_Publicacion

Biological Background of Resistance to Current Standards of Care in Multiple Myeloma

Abstract: A high priority problem in multiple myeloma (MM) management is the development of resistance to administered therapies, with most myeloma patients facing successively shorter periods of response and relapse. Herewith, we review the current knowledge on the mechanisms of resistance to the standard backbones in MM treatment: proteasome inhibitors (PIs), immunomodulatory agents (IMiDs), and monoclonal antibodies (mAbs). In some cases, strategies to overcome resistance have been discerned, and an effort should be made to evaluate whether resensitization to these agents is feasible in the clinical setting. Additionally, at a time in which we are moving towards precision medicine in MM, it is equally important to identify reliable and accurate biomarkers of sensitivity/refractoriness to these main therapeutic agents with the goal of having more efficacious treatments and, if possible, prevent the development of relapse.

 Fuente: Cells . 2019 Nov 13;8(11):1432

Editorial: MDPI

 Año de publicación: 2019

Nº de páginas: 18

Tipo de publicación: Artículo de Revista

 DOI: 10.3390/cells8111432

ISSN: 2073-4409

Url de la publicación: https://doi.org/10.3390/cells8111432

Autores/as

MOGOLLÓN, PEDRO

DÍAZ TEJEDOR, ANDREA

ALGARÍN, ESPERANZA M.

PAÍNO, TERESA

GARAYOA, MERCEDES